Zheng Z, Zhu Z, Zhou C, Cao L, Zhao G. Burden of Parkinson Disease in China, 1990–2019: findings from the 2019 global burden of Disease Study. Neuroepidemiology. 2023;57:51–63. https://doi.org/10.1159/000527372

Article  PubMed  Google Scholar 

Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 2019;18:459–80. https://doi.org/10.1016/s1474-4422(18)30499-x

Article  Google Scholar 

Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson Disease. JAMA. 2020;323:548–60. https://doi.org/10.1001/jama.2019.22360

Article  PubMed  Google Scholar 

Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20. https://doi.org/10.1016/s1474-4422(21)00030-2. :385 – 97.

Bidesi NSR, Vang Andersen I, Windhorst AD, Shalgunov V, Herth MM. The role of neuroimaging in Parkinson’s disease. J Neurochem. 2021;159:660–89. https://doi.org/10.1111/jnc.15516

Article  CAS  PubMed  PubMed Central  Google Scholar 

Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014;10:708–22. https://doi.org/10.1038/nrneurol.2014.205

Article  PubMed  Google Scholar 

Gee AD, Herth MM, James ML, Korde A, Scott PJH, Vasdev N. Radionuclide Imaging for Neuroscience: current opinion and future directions. Mol Imaging. 2020;19:1–9. https://doi.org/10.1177/1536012120936397

Article  Google Scholar 

Lameka K, Farwell MD, Ichise M. Positron Emission Tomography. Handb Clin Neurol. 2016;135:209–27. https://doi.org/10.1016/B978-0-444-53485-9.00011-8

Article  PubMed  Google Scholar 

Saeed U, Compagnone J, Aviv RI, Strafella AP, Black SE, Lang AE, et al. Imaging biomarkers in Parkinson’s disease and parkinsonian syndromes: current and emerging concepts. Transl Neurodegener. 2017;6:25. https://doi.org/10.1186/s40035-017-0076-6

Article  CAS  Google Scholar 

Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson’s Disease: recent Advancement. Neurosci Bull. 2017;33:585–97. https://doi.org/10.1007/s12264-017-0183-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stoessl AJ. Positron emission tomography in premotor Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:S421–4. https://doi.org/10.1016/s1353-8020(08)70041-5

Article  PubMed  Google Scholar 

Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol. 2000;47:493–503. https://doi.org/10.1002/1531-8249(200004)47:4%3C493::Aid-ana13%3E3.0.Co;2-4

Article  CAS  PubMed  Google Scholar 

Li T, Le W. Biomarkers for Parkinson’s Disease: how good are they? Neurosci Bull. 2019;36:183–94. https://doi.org/10.1007/s12264-019-00433-1

Article  PubMed  PubMed Central  Google Scholar 

Mitchell T, Lehéricy S, Chiu SY, Strafella AP, Stoessl AJ, Vaillancourt DE. Emerging neuroimaging biomarkers across Disease Stage in Parkinson Disease. JAMA Neurol. 2021;78:1262–72. https://doi.org/10.1001/jamaneurol.2021.1312

Article  PubMed  PubMed Central  Google Scholar 

Savchenko A, Targa G, Fesenko Z, Leo D, Gainetdinov RR, Sukhanov I. Dopamine transporter deficient rodents: perspectives and limitations for Neuroscience. Biomolecules. 2023;13:20. https://doi.org/10.3390/biom13050806

Article  CAS  Google Scholar 

Ng J, Barral S, Waddington SN, Kurian MA. Dopamine Transporter Deficiency Syndrome (DTDS): expanding the clinical phenotype and Precision Medicine approaches. Cells. 2023;12:1737. https://doi.org/10.3390/cells12131737

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brucke T, Brucke C. Dopamine transporter (DAT) imaging in Parkinson’s disease and related disorders. J Neural Transm (Vienna). 2022;129:581–94. https://doi.org/10.1007/s00702-021-02452-7

Article  CAS  PubMed  Google Scholar 

Mackie P, Lebowitz J, Saadatpour L, Nickoloff E, Gaskill P, Khoshbouei H. The dopamine transporter: an unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson’s Disease. Brain Behav Immun. 2018;70:21–35. https://doi.org/10.1016/j.bbi.2018.03.020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meles SK, Oertel WH, Leenders KL. Circuit imaging biomarkers in preclinical and prodromal Parkinson’s disease. Mol Med. 2021;27:111. https://doi.org/10.1186/s10020-021-00327-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller DB, O’Callaghan JP. Biomarkers of Parkinson’s disease: present and future. Metabolism. 2015;64:S40–6. https://doi.org/10.1016/j.metabol.2014.10.030

Article  CAS  PubMed  Google Scholar 

Xu J, Xu Q, Liu S, Li L, Li L, Yen T-C, et al. Computer-aided classification Framework of Parkinsonian disorders using 11C-CFT PET imaging. Front Aging Neurosci. 2022;13. https://doi.org/10.3389/fnagi.2021.792951

Dean F, Wong B, Yung RF, Dannals EK, Shaya, Hayden T, Ravert CA, Chen B, Chan T, Folio U, Scheffel GA, Ricaurte JL, Neumeyer HN, Wagner JR, AND, Michael J. Kuhar. In Vivo Imaging of Baboon and Human Dopamine Transporters by Positron Emission Tomography Using [11C]WIN 35,428. Synapse. 1993;15:130 – 42. https://doi.org/10.1002/syn.890150205

Park HS, Song YS, Moon BS, Yoo SE, Lee JM, Chung YT, et al. Neurorestorative effects of a Novel Fas-Associated factor 1 inhibitor in the MPTP Model: an [18F]FE-PE2I Positron Emission Tomography Analysis Study. Front Pharmacol. 2020;11. https://doi.org/10.3389/fphar.2020.00953

Serriere S, Tauber C, Vercouillie J, Guilloteau D, Deloye JB, Garreau L, et al. In vivo PET quantification of the dopamine transporter in rat brain with [18F]LBT-999. Nucl Med Biol. 2014;41:106–13. https://doi.org/10.1016/j.nucmedbio.2013.09.007

Article  CAS  PubMed  Google Scholar 

Cheon M, Kim SM, Ha S-W, Kang MJ, Yang H-E, Yoo J. Diagnostic performance for Differential diagnosis of atypical parkinsonian syndromes from Parkinson’s Disease using quantitative indices of 18F-FP-CIT PET/CT. Diagnostics. 2022;12:1402. https://doi.org/10.3390/diagnostics12061402

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palermo G, Ceravolo R. Molecular imaging of the dopamine transporter. Cells. 2019;8:872. https://doi.org/10.3390/cells8080872

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masilamoni G, Votaw J, Howell L, Villalba RM, Goodman M, Voll RJ, et al. 18F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Exp Neurol. 2010;226:265–73. https://doi.org/10.1016/j.expneurol.2010.08.024

Article  CAS  PubMed  PubMed Central  Google Scholar 

Margaret R, Davis JRV, Douglas Bremner J, Byas-Smith MG, Faber TL, Voll RJ, Hoffman JM, Scott T, Grafton CD, Kilts. Goodman. Initial Human PET Imaging Studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med. 2003;44:855–61. https://jnm.snmjournals.org/content/44/6/855.long

Google Scholar 

Sami S, Zoghbi H, Umesha Shetty M, Ichise M, Fujita M, Imaizumi J-S, Liow J, Shah JL, Musachio, Victor W, Pike. Innis. PET imaging of the dopamine transporter with 18F-FECNT: a Polar Radiometabolite confounds Brain Radioligand measurements. J Nucl Med. 2006;47:520–7. https://jnm.snmjournals.org/content/47/3/520.long

Google Scholar 

Kuchar M, Mamat C. Methods to increase the Metabolic Stability of 18F-Radiotracers. Molecules. 2015;20:16186–220. https://doi.org/10.3390/molecules200916186

Article  CAS  PubMed  PubMed Central  Google Scholar 

Timmins GS. Deuterated drugs: where are we now? Expert Opin Ther Pat. 2014;24:1067–75. https://doi.org/10.1517/13543776.2014.943184

Article  CAS  PubMed  PubMed Central  Google Scholar